Galbraith Kenneth's Insider Trades & SAST Disclosures
Galbraith Kenneth's most recent trade in Zymeworks BC Inc was a trade of 288,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Galbraith Kenneth.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 288,000 | 288,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 192,000 | 192,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 66,666 | 114,209 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 66,666 | 133,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 47,666 | 71,428 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 47,666 | 47,668 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 33,406 | 80,803 (0%) | 0% | 14.9 | 498,554 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 23,885 | 47,543 (0%) | 0% | 14.9 | 356,462 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 200,000 | 200,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 47,666 | 47,666 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 47,666 | 95,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Galbraith Kenneth | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 05 Jan 2024 | 18,198 | 29,468 (0%) | 0% | 10.7 | 193,849 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 05 Jan 2024 | 5,706 | 23,762 (0%) | 0% | 11.2 | 63,996 | Common Stock |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 215,000 | 215,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 143,000 | 143,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Kenneth Galbraith | Director, Chair, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Macrogenics Inc | Kenneth Galbraith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | Kenneth Galbraith | Director | Sale of securities on an exchange or to another person at price $ 27.11 per share. | 09 Sep 2020 | 13,849 | 0 (0%) | 0% | 27.1 | 375,446 | Common Stock |
| Macrogenics Inc | Kenneth Galbraith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2020 | 13,849 | 0 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | Kenneth Galbraith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 09 Sep 2020 | 13,849 | 13,849 (0%) | 0% | 16 | 221,584 | Common Stock |
| Macrogenics Inc | Kenneth Galbraith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Sep 2020 | 6,924 | 0 | - | - | Stock Option (right to buy) | |
| Macrogenics Inc | Kenneth Galbraith | Director | Sale of securities on an exchange or to another person at price $ 27.11 per share. | 09 Sep 2020 | 6,924 | 0 (0%) | 0% | 27.1 | 187,710 | Common Stock |
| Macrogenics Inc | Kenneth Galbraith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.15 per share. | 09 Sep 2020 | 6,924 | 6,924 (0%) | 0% | 20.2 | 139,519 | Common Stock |
| Macrogenics Inc | Kenneth Galbraith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges